The orally available, selective tyrosine kinase-2 inhibitor deucravacitinib met the primary and all secondary endpoints and improved quality of life in a randomized, double-blind, placebo-controlled phase 2 trial that included...
A large international survey showed that only few children with rheumatic diseases contracted COVID-19. None of these children required hospitalization or had severe disease outcomes, despite the intake of immunosuppressive...
Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients switching from placebo to guselkumab Guselkumab is the first and only U.S. FDA-approved selective...
COVID-19 and Patients with Rheumatic Disease on Biologic & Targeted Therapies : A Systematic Review Information about the outcomes of patients with rheumatic disease with SARS-CoV-2 infection is scarce. Patients with...
TUESDAY, Nov. 17, 2020 (HealthDay News) — In the older male population, there is a high...
A recent cohort study suggested a three-fold higher risk for knee osteoarthritis (OA) progression...
Current recommendations for testing of male osteoporosis patients are rather inconsistent, leading...
Data are lacking on whether patients with systemic autoimmune rheumatic diseases (SARDs)...
Despite research showing Kawasaki disease (KD) is associated with coronary artery aneurysms (CAAs)...
With few population-based studies assessing vasculitis-related mortality, most of which are...
